

The ubiquitin-proteasome pathway in cancer

British Journal of Cancer

77, 448-455

DOI: [10.1038/bjc.1998.71](https://doi.org/10.1038/bjc.1998.71)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 10403-10408.	3.3	881
2	Activation of the Cell Death Program by Nitric Oxide Involves Inhibition of the Proteasome. Journal of Biological Chemistry, 1999, 274, 19581-19586.	1.6	107
3	Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide Î±', Î²'-epoxyketones. Chemistry and Biology, 1999, 6, 811-822.	6.2	141
4	Cyclinâ€E dependent kinase activity in human breast cancer in relation to cyclinâ€E, p27 and p21 expression and retinoblastoma protein phosphorylation. Oncogene, 1999, 18, 2557-2566.	2.6	45
5	Ubiquitin-mediated proteolysis in learning and memory. Molecular Neurobiology, 1999, 20, 125-142.	1.9	52
6	Activation of the ubiquitin proteolytic system in murine acquired immunodeficiency syndrome affects I kappa Balpha turnover. FEBS Journal, 1999, 263, 202-211.	0.2	5
7	Impact of the expression of cyclin-dependent kinase inhibitor p27Kip1 and apoptosis in tumor cells on the overall survival of patients with non-Early stage gastric carcinoma. , 1999, 85, 1711-1718.		61
8	p53 and survival in early onset breast cancer: analysis of gene mutations, loss of heterozygosity and protein accumulation. European Journal of Cancer, 1999, 35, 1202-1207.	1.3	33
9	Discovering novel chemotherapeutic drugs for the third millennium. European Journal of Cancer, 1999, 35, 2010-2030.	1.3	134
10	Molecular mechanisms of CD8+ T cellâ€mediated delayed hypersensitivity: Implications for allergies, asthma, and autoimmunity. Journal of Allergy and Clinical Immunology, 1999, 103, 192-199.	1.5	142
11	PGP9.5 As a Candidate Tumor Marker for Non-Small-Cell Lung Cancer. American Journal of Pathology, 1999, 155, 711-715.	1.9	160
12	Glucose Starvation and Hypoxia Induce Nuclear Accumulation of Proteasome in Cancer Cells. Biochemical and Biophysical Research Communications, 1999, 258, 448-452.	1.0	32
13	Proteome analysis of breast cancer cells (8701-BC) cultured from primary ductal infiltrating carcinoma: relation to correspondent breast tissues. Breast Cancer Research, 2000, 2, 1.	2.2	2
14	Proteasome inhibitors as anti-cancer agents. Anti-Cancer Drugs, 2000, 11, 407-417.	0.7	42
15	Reduced stability of retinoblastoma protein by gankyrin, an oncogenic ankyrin-repeat protein overexpressed in hepatomas. Nature Medicine, 2000, 6, 96-99.	15.2	294
16	New agents in cancer clinical trials. Oncogene, 2000, 19, 6687-6692.	2.6	82
17	Proteasome inhibitors induce caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells. European Journal of Haematology, 2000, 65, 221-236.	1.1	81
18	Proteasome inhibition: a new strategy in cancer treatment. Investigational New Drugs, 2000, 18, 109-121.	1.2	223

#	ARTICLE	IF	CITATIONS
19	Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. <i>Blood</i> , 2000, 96, 269-274.	0.6	84
20	Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2000, 97, 1032-1037.	3.3	409
21	Ubiquitin-Proteasome System and Increased Sensitivity of B-CLL Lymphocytes to Apoptotic Death Activation. <i>Leukemia and Lymphoma</i> , 2000, 38, 499-504.	0.6	46
22	Estrogen receptor of primary breast cancers: evidence for intracellular proteolysis. <i>Breast Cancer Research</i> , 2000, 2, 444-54.	2.2	17
23	Crystal Structure of Epoxomicin:20S Proteasome Reveals a Molecular Basis for Selectivity of Î±-Epoxyketone Proteasome Inhibitors. <i>Journal of the American Chemical Society</i> , 2000, 122, 1237-1238.	6.6	304
24	Ubiquitin- and proteasome-dependent pathway of protein degradation as an emerging therapeutic target. <i>Expert Opinion on Therapeutic Targets</i> , 2000, 4, 89-111.	1.0	7
25	Pharmacological proteasome inhibitors and their therapeutic potential. <i>Expert Opinion on Therapeutic Patents</i> , 2000, 10, 1263-1272.	2.4	23
26	Proteases as Targets for Therapy. <i>Handbook of Experimental Pharmacology</i> , 2000, , .	0.9	9
27	Genetic Imbalances in Preleukemic Thymuses. <i>Biochemical and Biophysical Research Communications</i> , 2001, 283, 12-18.	1.0	17
28	Chemosensitization of Pancreatic Cancer by Inhibition of the 26S Proteasome. <i>Journal of Surgical Research</i> , 2001, 100, 11-17.	0.8	210
29	Identification of differentially expressed genes following treatment of monkey kidney cells with the mycotoxin fumonisin B1. <i>Food and Chemical Toxicology</i> , 2001, 39, 45-53.	1.8	21
30	A Proteomic Approach to the Identification of Lung Cancer Markers. <i>Disease Markers</i> , 2001, 17, 295-300.	0.6	57
31	Recent advances in breast cancer biology. <i>Current Opinion in Oncology</i> , 2001, 13, 415-419.	1.1	4
32	Proteasomes are a target of the anti-tumour drug vinblastine. <i>Biochemical Journal</i> , 2001, 356, 835.	1.7	17
33	Inherited renal cancer. <i>BJU International</i> , 2001, 86, 155-164.	1.3	5
34	Effect of the single major proteic fractions of the liver perchloric extract UK101 on the development of oral tumours in Syrian hamsters. <i>Journal of Oral Pathology and Medicine</i> , 2001, 30, 532-536.	1.4	2
35	Purification and identification of monoubiquitin-phosphoglycerate mutase B complex from human colorectal cancer tissues. <i>International Journal of Cancer</i> , 2001, 94, 662-668.	2.3	34
36	Ubiquitin and malignant transformation of oral mucosa. <i>Head and Neck</i> , 2001, 23, 972-978.	0.9	2

#	ARTICLE	IF	CITATIONS
37	Expression of the Protein Gene Product 9.5, PGP9.5, is Correlated with T-status in Non-small Cell Lung Cancer. Japanese Journal of Clinical Oncology, 2001, 31, 532-535.	0.6	51
38	Nuclear Import/Export of hRPF1/Nedd4 Regulates the Ubiquitin- dependent Degradation of Its Nuclear Substrates. Journal of Biological Chemistry, 2001, 276, 26324-26331.	1.6	46
39	Butyrate Suppression of Colonocyte NF- κ B Activation and Cellular Proteasome Activity. Journal of Biological Chemistry, 2001, 276, 44641-44646.	1.6	234
40	Chromosomal DNA and p53 Stability, Ubiquitin System and Apoptosis in B-CLL Lymphocytes. Leukemia and Lymphoma, 2001, 42, 1173-1180.	0.6	9
41	The Corepressor mSin3a Interacts with the Proline-Rich Domain of p53 and Protects p53 from Proteasome-Mediated Degradation. Molecular and Cellular Biology, 2001, 21, 3974-3985.	1.1	117
42	The proteasome: a novel target for cancer chemotherapy. Leukemia, 2002, 16, 433-443.	3.3	497
43	Sequencing, Transcript Identification, and Quantitative Gene Expression Profiling in the Breast Cancer Loss of Heterozygosity Region 16q24.3 Reveal Three Potential Tumor-Suppressor Genes. Genomics, 2002, 80, 303-310.	1.3	42
44	Overexpression of p28/gankyrin in human hepatocellular carcinoma and its clinical significance. World Journal of Gastroenterology, 2002, 8, 638.	1.4	88
45	Cellular drug action profile paradigm applied to XK469. Journal of Experimental Therapeutics and Oncology, 2002, 2, 253-263.	0.5	6
46	Effects of inhibition of ubiquitin-proteasome pathway on human primary leukemic cells. Science in China Series C: Life Sciences, 2002, 45, 647-655.	1.3	0
47	Genome-wide search of Schizosaccharomyces pombe genes causing overexpression-mediated cell cycle defects. Yeast, 2002, 19, 1139-1151.	0.8	23
48	Transcription factor E2F-1 acts as a growth-promoting factor and is associated with adverse prognosis in non-small cell lung carcinomas. Journal of Pathology, 2002, 198, 142-156.	2.1	143
49	Identification of genes regulated by Dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene, 2002, 21, 1346-1358.	2.6	170
50	Identification of genes over-expressed in small cell lung carcinoma using suppression subtractive hybridization and cDNA microarray expression analysis. Oncogene, 2002, 21, 3814-3825.	2.6	64
51	Expression of RALT, a feedback inhibitor of ErbB receptors, is subjected to an integrated transcriptional and post-translational control. Oncogene, 2002, 21, 6530-6539.	2.6	73
52	Role and Function of the 26S Proteasome in Proliferation and Apoptosis. Laboratory Investigation, 2002, 82, 965-980.	1.7	237
53	Papillomaviruses and cancer: from basic studies to clinical application. Nature Reviews Cancer, 2002, 2, 342-350.	12.8	3,356
54	Cachexia in cancer patients. Nature Reviews Cancer, 2002, 2, 862-871.	12.8	806

#	ARTICLE	IF	CITATIONS
55	Overexpression of cyclin E protein is closely related to the mutator phenotype of colorectal carcinoma. <i>International Journal of Colorectal Disease</i> , 2002, 17, 374-380.	1.0	20
56	Autophagy: a barrier or an adaptive response to cancer. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2003, 1603, 113-128.	3.3	165
57	Defective expression of the T-cell receptor-CD3 ζ chain in T-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2003, 120, 201-208.	1.2	18
58	p62 overexpression in breast tumors and regulation by prostate-derived Ets factor in breast cancer cells. <i>Oncogene</i> , 2003, 22, 2322-2333.	2.6	161
59	Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer. <i>Journal of Surgical Research</i> , 2003, 113, 88-95.	0.8	57
60	Calcium- and Proteasome-dependent Degradation of the JNK Scaffold Protein Islet-brain 1. <i>Journal of Biological Chemistry</i> , 2003, 278, 48720-48726.	1.6	18
61	Cloning and Characterization of N4WBP5A, an Inducible, Cyclosporine-sensitive, Nedd4-binding Protein in Human T Lymphocytes. <i>Journal of Biological Chemistry</i> , 2003, 278, 34587-34597.	1.6	19
62	Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. <i>Blood</i> , 2003, 101, 3606-3614.	0.6	67
63	Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene. <i>Journal of Clinical Investigation</i> , 2003, 112, 1809-1820.	3.9	1,957
64	Peroxisome Proliferator-activated Receptor γ^2 (γ^2)-dependent Regulation of Ubiquitin C Expression Contributes to Attenuation of Skin Carcinogenesis. <i>Journal of Biological Chemistry</i> , 2004, 279, 23719-23727.	1.6	85
65	Expression of protein gene product 95 (PGP95)/ubiquitin-C-terminal hydrolase 1 (UCHL-1) in human myeloma cells. <i>British Journal of Haematology</i> , 2004, 127, 292-298.	1.2	47
66	Suppression subtractive hybridization and expression profiling identifies a unique set of genes overexpressed in non-small-cell lung cancer. <i>Oncogene</i> , 2004, 23, 7734-7745.	2.6	67
67	Proteasome inhibitors and their combination with antiandrogens: effects on apoptosis, cellular proliferation and viability of prostatic adenocarcinoma cell cultures. <i>Prostate Cancer and Prostatic Diseases</i> , 2004, 7, 138-143.	2.0	9
68	Novel therapeutic targets in squamous cell carcinoma of the head and neck. <i>Seminars in Oncology</i> , 2004, 31, 755-768.	0.8	19
69	A new structural class of proteasome inhibitors identified by microbial screening using yeast-based assay. <i>Biochemical Pharmacology</i> , 2004, 67, 227-234.	2.0	75
70	The emerging role of bortezomib in the treatment of indolent non-hodgkinian™ and mantle cell lymphomas. <i>Current Treatment Options in Oncology</i> , 2004, 5, 269-281.	1.3	14
71	Proteome analysis of hepatocellular carcinoma cell strains, MHCC97-H and MHCC97-L, with different metastasis potentials. <i>Proteomics</i> , 2004, 4, 982-994.	1.3	143
72	The role of proteasome inhibitors in solid tumors. <i>Annals of Medicine</i> , 2004, 36, 296-303.	1.5	30

#	ARTICLE	IF	CITATIONS
74	Quantitative analysis of free ubiquitin and multi-ubiquitin chain in colorectal cancer. <i>Cancer Letters</i> , 2004, 211, 111-117.	3.2	20
75	Elevated expression level of 60-kDa subunit of tRNA-guanine transglycosylase in colon cancer. <i>Cancer Letters</i> , 2004, 212, 113-119.	3.2	10
76	PGP9.5 mRNA could contribute to the molecular-based diagnosis of medullary thyroid carcinoma. <i>European Journal of Cancer</i> , 2004, 40, 614-618.	1.3	31
77	cDNA representational difference analysis of the deltamethrin-resistant and -susceptible populations in diamondback moth (<i>Plutella xylostella</i> L.). <i>Journal of Applied Entomology</i> , 2005, 129, 515-520.	0.8	6
78	Molecular characterization of tumour heterogeneity and malignant mesothelioma cell differentiation by gene profiling. <i>Journal of Pathology</i> , 2005, 207, 91-101.	2.1	37
79	Proteasome Inhibition and Its Clinical Application in Solid Tumors. , 2005, , 493-507.		0
80	Effects of the proteasome inhibitor bortezomib on osteolytic human prostate cancer cell metastases. <i>Prostate Cancer and Prostatic Diseases</i> , 2005, 8, 327-334.	2.0	17
81	Peroxisome Proliferator-activated Receptor- γ Inhibits Epidermal Cell Proliferation by Down-regulation of Kinase Activity. <i>Journal of Biological Chemistry</i> , 2005, 280, 9519-9527.	1.6	81
82	MDM2 Promotes Proteasome-Dependent Ubiquitin-Independent Degradation of Retinoblastoma Protein. <i>Molecular Cell</i> , 2005, 20, 699-708.	4.5	239
83	New insights on brain stem death: From bedside to bench. <i>Progress in Neurobiology</i> , 2005, 77, 396-425.	2.8	45
84	Proteasome Inhibition As a Novel Therapeutic Target in Human Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 630-639.	0.8	526
85	Measuring Ubiquitin Conjugation in Cells. , 2005, 301, 223-242.		14
86	Mechanistic Rationale and Clinical Evidence for the Efficacy of Proteasome Inhibitors against Indolent and Mantle Cell Lymphomas. <i>BioDrugs</i> , 2006, 20, 13-23.	2.2	24
87	Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. <i>Nature Clinical Practice Oncology</i> , 2006, 3, 374-387.	4.3	103
88	Ubiquitin-Proteasome Pathway Function Is Required for Lens Cell Proliferation and Differentiation. , 2006, 47, 2569.		30
89	Ubiquitin-specific protease 14 expression in colorectal cancer is associated with liver and lymph node metastases. <i>Oncology Reports</i> , 2006, 15, 539.	1.2	45
90	Mechanism of Action of Camptothecin. <i>Annals of the New York Academy of Sciences</i> , 2000, 922, 1-10.	1.8	383
91	High expression of ubiquitin carboxy-terminal hydrolase-L1 and -L3 mRNA predicts early recurrence in patients with invasive breast cancer. <i>Cancer Science</i> , 2006, 97, 523-529.	1.7	85

#	ARTICLE	IF	CITATIONS
92	Hypomethylation of the protein gene product 9.5 promoter region in gallbladder cancer and its relationship with clinicopathological features. <i>Cancer Science</i> , 2006, 97, 1205-1210.	1.7	39
93	Proteasome inhibitor bortezomib for the treatment of multiple myeloma. <i>Leukemia</i> , 2006, 20, 1341-1352.	3.3	115
94	Lactacystin Exhibits Potent Anti-tumor Activity in an Animal Model of Malignant Glioma when Administered via Controlled-release Polymers. <i>Journal of Neuro-Oncology</i> , 2006, 77, 225-232.	1.4	20
95	Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 58, 13-23.	1.1	118
96	Inhibition of the Proteasomal Function in Chondrocytes Down-Regulates Growth Plate Chondrogenesis and Longitudinal Bone Growth. <i>Endocrinology</i> , 2006, 147, 3761-3768.	1.4	23
97	Immunohistochemical Detection of Protein Gene Product 9.5 (PGP 9.5) in Canine Epitheliotropic T-Cell Lymphoma (Mycosis Fungoides). <i>Veterinary Pathology</i> , 2007, 44, 74-79.	0.8	26
98	Ubiquitin COOH-Terminal Hydrolase 1: A Biomarker of Renal Cell Carcinoma Associated with Enhanced Tumor Cell Proliferation and Migration[?Q1: Running head: UCHL1, a Biomarker of RCC. Short title OK?Q1]. <i>Clinical Cancer Research</i> , 2007, 13, 27-37.	3.2	55
99	Immediate early gene-X1 interferes with 26S proteasome activity by attenuating expression of the 19 S proteasomal components S5a/Rpn10 and S1/Rpn2. <i>Biochemical Journal</i> , 2007, 402, 367-375.	1.7	16
100	NF- κ B-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs. <i>Blood</i> , 2007, 109, 3982-3988.	0.6	47
101	A proteomics approach to identify the ubiquitinated proteins in mouse heart. <i>Biochemical and Biophysical Research Communications</i> , 2007, 357, 731-736.	1.0	92
102	Involvement of nPKC-MAPK pathway in the decrease of nucleophosmin/B23 during megakaryocytic differentiation of human myelogenous leukemia K562 cells. <i>Life Sciences</i> , 2007, 80, 2051-2059.	2.0	8
103	Signaling Chains. , 2007, , 189-214.		2
104	Gene expression profiling of human gliomas reveals differences between GBM and LGA related to energy metabolism and notch signaling pathways. <i>Journal of Molecular Neuroscience</i> , 2007, 32, 53-63.	1.1	23
105	Pyrrolidine dithiocarbamate-zinc(II) and -copper(II) complexes induce apoptosis in tumor cells by inhibiting the proteasomal activity. <i>Toxicology and Applied Pharmacology</i> , 2008, 231, 24-33.	1.3	126
106	Chaperone-driven proteasome assembly. <i>Biochemical Society Transactions</i> , 2008, 36, 807-812.	1.6	35
107	Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels. <i>Clinical Cancer Research</i> , 2008, 14, 1561-1570.	3.2	213
108	Useful Markers for Detecting Minimal Residual Disease in Cases of Neuroblastoma. <i>Biological and Pharmaceutical Bulletin</i> , 2008, 31, 1071-1074.	0.6	19
109	Targeting NF- κ B in Waldenstrom macroglobulinemia. <i>Blood</i> , 2008, 111, 5068-5077.	0.6	106

#	ARTICLE	IF	CITATIONS
110	The proteasome subunit PSMA7 located on the 20q13 amplicon is overexpressed and associated with liver metastasis in colorectal cancer. <i>Oncology Reports</i> , 2008, , .	1.2	16
111	Proteasome Inhibition: Thinking outside the Box. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S3072.	0.1	0
112	Proteasomeâ€“NFÎ² Signaling Pathway: Relevance in RCC. , 2009, , 305-320.		0
114	Knockdown of the novel proteasome subunit Adrm1 located on the 20q13 amplicon inhibits colorectal cancer cell migration, survival and tumorigenicity. <i>Oncology Reports</i> , 2009, , .	1.2	5
115	PGP 9.5 expression in cutaneous keratoacanthomas and squamous cell carcinomas. <i>Archives of Dermatological Research</i> , 2009, 301, 653-658.	1.1	5
116	Epigenetic control of the ubiquitin carboxyl terminal hydrolase 1 in renal cell carcinoma. <i>Journal of Translational Medicine</i> , 2009, 7, 90.	1.8	26
117	Inhibition of tumor proteasome activity by goldâ€“dithiocarbamate complexes via both redoxâ€“dependent and â€“independent processes. <i>Journal of Cellular Biochemistry</i> , 2010, 109, 162-172.	1.2	106
118	Differentially expressed proteins of MCFâ€“7 human breast cancer cells affected by Zilongjin, a complementary Chinese herbal medicine. <i>Proteomics - Clinical Applications</i> , 2010, 4, 550-559.	0.8	5
119	A Proteasome Inhibitor, Bortezomib, Inhibits Breast Cancer Growth and Reduces Osteolysis by Downregulating Metastatic Genes. <i>Clinical Cancer Research</i> , 2010, 16, 4978-4989.	3.2	58
120	Interferon-â² induces p21cip1/waf1 degradation and cell proliferation in HeLa cells. <i>Cell Cycle</i> , 2010, 9, 131-139.	1.3	13
121	Differential Effects of the Proteasome Inhibitor NPI-0052 against Glioma Cells. <i>Translational Oncology</i> , 2010, 3, 50-55.	1.7	27
122	Uterine Tumors. , 2011, , 3865-3865.		1
123	Differential Transcriptomic Analysis of Spontaneous Lung Tumors in B6C3F1 Mice: Comparison to Human Nonâ€“Small Cell Lung Cancer. <i>Toxicologic Pathology</i> , 2012, 40, 1141-1159.	0.9	23
124	Roles of Estrogen Receptor and p21Waf1 in Bortezomib-Induced Growth Inhibition in Human Breast Cancer Cells. <i>Molecular Cancer Research</i> , 2012, 10, 1473-1481.	1.5	5
125	Sequestosome 1/p62: across diseases. <i>Biomarkers</i> , 2012, 17, 99-103.	0.9	44
126	A Systematic Phenotypic Screen of F-box Genes Through a Tissue-specific RNAi-based Approach in <i>Drosophila</i> . <i>Journal of Genetics and Genomics</i> , 2012, 39, 397-413.	1.7	14
127	The COP9 signalosome counteracts the accumulation of cullin SCF ubiquitin E3 RING ligases during fungal development. <i>Molecular Microbiology</i> , 2012, 83, 1162-1177.	1.2	40
128	The 26S proteasome complex: An attractive target for cancer therapy. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2012, 1825, 64-76.	3.3	127

#	ARTICLE	IF	CITATIONS
129	High expression of P53-induced Ring-h2 protein is associated with poor prognosis in clear cell renal cell carcinoma. <i>European Journal of Surgical Oncology</i> , 2013, 39, 100-106.	0.5	10
130	Proteomic profiling of expression of proteasomal subunits from livers of mice treated with diethylnitrosamine. <i>Proteomics</i> , 2013, 13, 389-397.	1.3	4
131	Nucleosome acetyltransferase 10 protein is a negative regulator of 28S proteasome through interaction with PA28 β . <i>FEBS Letters</i> , 2013, 587, 1630-1637.	1.3	16
132	Proteasome Inhibition as a Novel Strategy for Cancer Treatment. , 2013, , 303-329.		2
134	How Numbers, Nature, and Immune Status of Foxp3+ Regulatory T-Cells Shape the Early Immunological Events in Tumor Development. <i>Frontiers in Immunology</i> , 2013, 4, 292.	2.2	38
135	Proteomic identification of protein ubiquitination events. <i>Biotechnology and Genetic Engineering Reviews</i> , 2013, 29, 73-109.	2.4	54
136	Crude and purified proteasome activity assays are affected by type of microplate. <i>Analytical Biochemistry</i> , 2014, 446, 44-52.	1.1	25
137	A Novel Intracellular Peptide Derived from G1/S Cyclin D2 Induces Cell Death. <i>Journal of Biological Chemistry</i> , 2014, 289, 16711-16726.	1.6	42
138	Heat shock protein 90 β stabilizes focal adhesion kinase and enhances cell migration and invasion in breast cancer cells. <i>Experimental Cell Research</i> , 2014, 326, 78-89.	1.2	26
139	The role of ginsenosides in inhibiting ubiquitin activating enzyme (E1) activity. <i>Journal of Functional Foods</i> , 2014, 7, 462-470.	1.6	11
140	Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes. <i>Therapeutics and Clinical Risk Management</i> , 2015, 11, 1663.	0.9	1
141	Homology modeling and virtual screening of ubiquitin conjugation enzyme E2A for designing a novel selective antagonist against cancer. <i>Journal of Receptor and Signal Transduction Research</i> , 2015, 35, 536-549.	1.3	22
142	Role of Nrf2, HO-1 and GSH in Neuroblastoma Cell Resistance to Bortezomib. <i>PLoS ONE</i> , 2016, 11, e0152465.	1.1	45
143	The fine-tuning of proteolytic pathways in Alzheimer's disease. <i>Cellular and Molecular Life Sciences</i> , 2016, 73, 3433-3451.	2.4	16
144	Perspectives on targeting the phosphatidylinositol 3-kinase pathway for personalized medicine in endometrial and ovarian cancers. <i>Personalized Medicine Universe</i> , 2016, 5, 3-7.	0.1	0
145	Engineering and In Vitro Evaluation of Acid Labile Cholesterol Tethered MG132 Nanoparticle for Targeting Ubiquitin-Proteasome System in Cancer. <i>ChemistrySelect</i> , 2016, 1, 5099-5106.	0.7	0
146	Potential peptidic proteasome inhibitors by incorporation of an electrophilic trap based on amino acid derived α -substituted sulfonyl fluorides. <i>Bioorganic and Medicinal Chemistry</i> , 2017, 25, 5055-5063.	1.4	16
147	Machine Learning-Assisted Network Inference Approach to Identify a New Class of Genes that Coordinate the Functionality of Cancer Networks. <i>Scientific Reports</i> , 2017, 7, 6993.	1.6	37

#	ARTICLE	IF	CITATIONS
148	Lewis y antigen promotes p27 degradation by regulating ubiquitin-proteasome activity. <i>Oncotarget</i> , 2017, 8, 110064-110076.	0.8	6
149	RAS-Like Protein. , 2018, , 4497-4497.		0
150	RhoGEF Kinase. , 2018, , 4699-4699.		0
151	Rotamase. , 2018, , 4752-4752.		0
152	Ramp. , 2018, , 4433-4438.		0
153	Anticancer study of heterobimetallic platinum(II)-ruthenium(II) and platinum(II)-rhodium(III) complexes with bridging dithiooxamide ligand. <i>Journal of Organometallic Chemistry</i> , 2019, 900, 120918.	0.8	15
154	Synthesis, solution behaviour and potential anticancer activity of new trinuclear organometallic palladium(II) complex of {S}-1-phenylethyl dithiooxamide: Comparison with the trinuclear heterobimetallic platinum(II) analogue. <i>Polyhedron</i> , 2019, 164, 195-201.	1.0	9
155	<p></p>RNA-Seq Analysis Identified XLOC_009190 as Potential Therapeutic Target for Lung Adenocarcinoma</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 11221-11229.	1.0	0
156	Diverse roles of the E2/E3 hybrid enzyme <sc>UBE</sc>2O in the regulation of protein ubiquitination, cellular functions, and disease onset. <i>FEBS Journal</i> , 2019, 286, 2018-2034.	2.2	28
157	Quantitative structure-activity relationship and molecular docking studies on human proteasome inhibitors for anticancer activity targeting NF- κ B signaling pathway. <i>Journal of Biomolecular Structure and Dynamics</i> , 2020, 38, 3621-3632.	2.0	3
158	SVFX: a machine learning framework to quantify the pathogenicity of structural variants. <i>Genome Biology</i> , 2020, 21, 274.	3.8	24
159	Fluorescent Probes with Unnatural Amino Acids to Monitor Proteasome Activity in Real-Time. <i>ACS Chemical Biology</i> , 2020, 15, 2588-2596.	1.6	22
160	TERT Promoter Mutations and Their Impact on Gene Expression Profile in Papillary Thyroid Carcinoma. <i>Cancers</i> , 2020, 12, 1597.	1.7	13
161	Kaposi's Sarcoma-Associated Herpesvirus Infection Induces the Expression of Neuroendocrine Genes in Endothelial Cells. <i>Journal of Virology</i> , 2020, 94, .	1.5	10
162	Theoretical Studies of the Acid-Base Equilibria in a Model Active Site of the Human 20S Proteasome. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 1942-1953.	2.5	4
163	The emerging role of cellular post-translational modifications in modulating growth and productivity of recombinant Chinese hamster ovary cells. <i>Biotechnology Advances</i> , 2021, 49, 107757.	6.0	14
164	Molecular switches that govern the balance between proliferation and apoptosis. , 2000, 4, 207-217.		26
165	Regulating the 26S Proteasome. <i>Current Topics in Microbiology and Immunology</i> , 2002, 268, 43-72.	0.7	27

#	ARTICLE	IF	CITATIONS
167	Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. <i>Blood</i> , 2000, 96, 269-274.	0.6	5
168	Different Effect of Proteasome Inhibition on Vesicular Stomatitis Virus and Poliovirus Replication. <i>PLoS ONE</i> , 2008, 3, e1887.	1.1	38
169	UBIQUITIN CYTOCHEMICAL CHANGES DURING AZASERINE-INITIATED PANCREATIC CARCINOGENESIS. <i>Acta Biologica Hungarica</i> , 2001, 52, 383-391.	0.7	7
170	Pioglitazone, a PPAR-gamma ligand, exerts cytostatic/cytotoxic effects against cancer cells, that do not result from inhibition of proteasome.. <i>Acta Biochimica Polonica</i> , 2008, 55, 75-84.	0.3	6
171	The small heat shock protein B8 (HSPB8) confers resistance to bortezomib by promoting autophagic removal of misfolded proteins in multiple myeloma cells. <i>Oncotarget</i> , 2014, 5, 6252-6266.	0.8	43
172	Gene and protein expressions of p28 ^{GANK} in rat with liver regeneration. <i>World Journal of Gastroenterology</i> , 2003, 9, 2523.	1.4	11
173	Targeted Protein Degradation: Current Status and Future Prospects. <i>Research Journal of Pharmacy and Technology</i> , 2021, , 5047-5050.	0.2	0
174	Proteasome and Apoptosis. <i>Handbook of Experimental Pharmacology</i> , 2000, , 341-358.	0.9	0
176	Selected Targets and Rationally Designed Therapeutics for Patients with Colorectal Cancer. , 2002, , 759-793.		0
177	A Genomic Approach to the Treatment of Breast Cancer. , 2002, , 393-401.		0
178	Genome-Wide Analysis of Gene Expression in Hepatocellular Carcinoma. , 2004, , 74-83.		0
179	Ubiquitination. , 2011, , 3827-3832.		0
180	RPN8. , 2012, , 1691-1694.		0
181	RPN8. , 2018, , 4752-4756.		0
182	Pharmacological Modulation of Ubiquitin-Proteasome Pathways in Oncogenic Signaling. <i>International Journal of Molecular Sciences</i> , 2021, 22, 11971.	1.8	42
183	Targeted Therapies in Head and Neck Cancer. , 2005, , 239-261.		0
184	SPOP and cancer: a systematic review. <i>American Journal of Cancer Research</i> , 2020, 10, 704-726.	1.4	15
185	Effects of the proteasome inhibitor ritonavir on glioma growth <i>in vitro</i> and <i>in vivo</i> . <i>Molecular Cancer Therapeutics</i> , 2004, 3, 129-136.	1.9	63

#	ARTICLE	IF	CITATIONS
186	Glioblastoma multiforme in patients with human immunodeficiency virus: an integrated review and analysis. <i>Journal of Neuro-Oncology</i> , 2022, 159, 571-579.	1.4	2
187	Prognosis of Non-Small Cell Lung Cancer Patients by Detecting Circulating Cancer Cells in the Peripheral Blood with Multiple Marker Genes. <i>Clinical Cancer Research</i> , 2005, 11, 173-179.	3.2	89
188	Protein Synthesis/Degradation: Protein Degradation in Intracellular Ubiquitin, Ubiquitin-Like Proteins, and Proteasome-Mediated Degradation. , 2022, , .		0
189	Astaxanthin Inhibits Oxidative Stress-Induced Ku Protein Degradation and Apoptosis in Gastric Epithelial Cells. <i>Nutrients</i> , 2022, 14, 3939.	1.7	2
190	Chlorogenic acid modulates the ubiquitin-proteasome system in stroke animal model. <i>Laboratory Animal Research</i> , 2022, 38, .	1.1	0
191	Unravelling the genetic links between Parkinson's disease and lung cancer. <i>Biological Chemistry</i> , 2023, 404, 551-567.	1.2	1